Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma

Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma

Servier is expanding its cancer drug prospects through the $2.5 billion acquisition of Day One Biopharmaceuticals, a biotech with a commercialized therapy for a type of pediatric glioma and clinical-stage assets that fit the French company’s business strategy of pipeline and revenue growth, particularly in oncology.Per acquisition terms announced Friday, Servier will pay $21.50 in cash for each share of Day One, which is a 68% premium to the sto…

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals shares traded at $21.24 Monday, just below Servier’s $21.50-per-share cash offer in a $2.5 billion takeover. The deal would give Servier Ojemda, the only U.S.-approved single-drug treatment for pediatric low-grade glioma, with 2025 sales of $155.4 million. The tender offer has not started and closing depends on shareholder response and U.S. antitrust clearance. The post Day One Biopharmaceuticals, Inc. Buyout: Why Serv…

Servier buys Day One for $2.5bn to bolster its rare cancer pipeline - European Biotechnology Magazine

French pharma giant Servier is spending US$2.5bn to snap up Day One Biopharmaceuticals, gaining a key approved drug for difficult childhood brain tumours along with several promising pipeline candidates. The post Servier buys Day One for $2.5bn to bolster its rare cancer pipeline appeared first on European Biotechnology Magazine.